Open AccessA review of pharmacogenetic aspects of methotrexate and 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia treatment
Author(s) -
О. Д. Гурьева,
М. И. Савельева,
Т. Т. Валиев
Publication year - 2021
Publication title -
rossijskij žurnal detskoj gematologii i onkologii
Language(s) - English
Resource type - Journals
eISSN - 2413-5496
pISSN - 2311-1267
DOI - 10.21682/2311-1267-2021-8-3-79-85
Subject(s) - pharmacogenetics , mercaptopurine , methotrexate , medicine , toxicity , drug , pharmacology , lymphoblastic leukemia , oncology , leukemia , intensive care medicine , genotype , biology , gene , biochemistry
Significant progress in the treatment of acute lymphoblastic leukemia (ALL) in children has resulted from the development of effective chemoand supportive care therapy protocols. The vector of further research is aimed at reducing toxicity and long-term side effects. The study of pharmacogenetic aspects of toxicity of the main drugs used in the treatment of ALL – methotrexate and 6-mercaptopurine – allowed to identify oligonucleotide polymorphisms that correlate with the concentration of the drug in blood, toxic effects and the risk of relapse of ALL. The clinical administration of pharmacogenetic methods remains a challenging task, requiring additional research, which will make it possible to individualize the ALL therapy on the basis of the results of molecular profiling.